Diabetic Peripheral Neuropathy

Researchers in Endocrinology at the university of Tor Vergata, Rome, published a review of available literature  dealing with the similarities and differences between painful and painless DPN to try and determine if whether they are the same disease. Some people develop an ‘insensate’ variety of DPN while others experience distressing pain.  READ MORE Source: Curr Diab Rep

A team of researchers from the Department of Neurology, Northwestern University, reported on Phase 1/2 results of a study to evaluate the safety and preliminary efficacy of intramuscular injections of plasmid DNA (VM202) expressing two isoforms of hepatocyte growth factor (HGF) in patients with painful diabetic peripheral neuropathy (PDPN). Initial results are that VM202 treatment appeared …

Phase 1/2 Open-label Dose-escalation Study of Plasmid DNA Expressing Two Isoforms of Hepatocyte Growth Factor in Patients with Painful Diabetic Peripheral Neuropathy Read More »

Findings from 3 proof-of-concept studies have been published evaluating the efficacy and safety of carisbamate, a novel neurotherapeutic agent, in the treatment of neuropathic pain. Studies were conducted with patients having postherpetic neuralgia or diabetic peripheral neuropathy for up to 15 weeks. Carisbamate, though well tolerated, did not demonstrate efficacy in neuropathic pain; neither did the …

Efficacy and Safety of Carisbamate in Patients with Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Read More »

Joanne Moser, MSN, CRNO, and a team of researchers have published a report asking for new guidelines for detection of diabetic peripheral neuropathy in children. Of the 151 children in their study, 26% had a positive screening test for DPN.  READ MORE Source: NewsMedical

The total cost of diabetes in the US jumped from $174 billion in 2007, to $245 billion in 2012. Costs in 2012 included $176 billion in direct medical costs and $69 billion in indirect costs, which includes absenteeism, reduced productivity, and unemployment caused by disease-related disability. The full report will be published in the April issue of Diabetes Care.  …

Cost of Diabetes Care in US Keeps Climbing Read More »

Pfizer, Inc. supported a study to characterize the burden of illness among adult patients with DPN receiving treatment in the US. They recruited 112 patients during routine visits at general practitioners and specialist sites who completed a one-time questionnaire that included symptom duration, out-of-pocket costs, validated pain measures, and other assessments. The full study and conclusions are …

Burden of Illness Associated with Painful Diabetic Peripheral Neuropathy Among Adults Seeking Treatment in the US Read More »

Dr. Alessandra Martinelli and her colleagues from the School of Science and Technology in Brazil, evaluated the spatial variables of gait and isometric muscle strength in patients with diabetic peripheral neuropathy. They found that the ankle, muscle strength, and ankle mobility variables could explain differences differences in gait speed and range of motion.  READ MORE …

Gait Abnormalities Found in Diabetic Neuropathy Read More »